Please login to the form below

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

Incyte’s JAK inhibitor cream clears second eczema trial

The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for

Latest news

Vyndaqel a bright spot as Pfizer comes under pressure

The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... Ibrance was up 15% to $1.28bn in the quarter,
GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

This includes its CDK 4/6 inhibitor Ibrance (palbociclib), which grew by 27% to $1.3bn in the last quarter, and its fast-growing oral JAK inhibitor Xeljanz (tofacitinib).
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis

This includes a number of patient organisations who argue that drugs like Rinvoq and Pfizer’s JAK inhibitor Xeljanz (tofacitinib) have created real improvements for people living with the condition.
J&J splashes $750m on anti-inflammatory drug bermekimab

As well as facing competition from Cosentyx and Skyrizi, Tremfya also has to contend with Eli Lilly’s IL-17 inhibitor Taltz (ixekizumab) and Pfizer’s oral JAK inhibitor Xeljanz (tofacitinib),
UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

This includes a new class of JAK inhibitors, such as AbbVie’s Rinvoq (upadacitinib), Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).

More from news
Approximately 19 fully matching, plus 62 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Manager (PR): Great Benefits

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Account director: Competitive salary and bonus scheme

Account Director: £Competitive Salary

Account Director, Medical Education: Salary TBC

Senior External Communications Lead: £Competitive Salary

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Account Manager: £Competitive Salary

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Publications director: Competitive salary and bonus scheme

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Experienced medical editor: Competitive salary and bonus scheme

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Subscribe to our email news alerts

PMHub

Add my company

JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The ALS patient journey: Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape: Dr Tyler Ray, OPEN Health Medical Communications...
Can protein degraders unlock ‘undruggable’ drug targets?: Exploring a new and exciting area of small-molecule drug discovery...